Pyoderma gangrenosum
Pyoderma gangrenosum is in seldsum, inflamatorisch hûdsykte wêrby't pynlike pustules of knobbels úlceraas wurde dy't stadichoan groeie. Pyoderma gangrenosum is net besmetlik. Behannelingen kinne omfetsje corticosteroïden, ciclosporine, of ferskate monoklonale antykladen. Hoewol it minsken fan elke leeftyd kin beynfloedzje, hat it meast ynfloed op minsken yn harren 40- en 50-jierrûnen.
☆ AI Dermatology — Free Service
Yn 'e 2022 Stiftung Warentest-resultaten út Dútslân wie de konsuminttefredenheid mei ModelDerm mar wat leger dan mei betelle telemedisynkonsultaasjes.
Yn 'e 2022 Stiftung Warentest-resultaten út Dútslân wie de konsuminttefredenheid mei ModelDerm mar wat leger dan mei betelle telemedisynkonsultaasjes.
Op de hûd fan in persoan mei ulcerative kolitis.
relevance score : -100.0%
ReferencesPyoderma gangrenosum is in seldsume hûdbetingst dy't pynlike wonden feroarsaket mei reade of pearse rânen. It is klassifisearre as in inflammatoire sykte en is diel fan in groep neamd neutrofiele dermatoses. De oarsaak fan Pyoderma gangrenosum is kompleks, mei problemen mei sawol oanbarde as adaptieve immuniteit yn minsken dy't genetysk gefoelich binne. Koartlyn hawwe ûndersikers har rjochte op de hierfollikel as in mooglik útgongspunt fan de sykte.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum is in seldsum hûdkondysje dy't ekstreem pynlike wonden feroarsaket. Wylst wy de oarsaak net folslein begripe, witte wy dat it om ferhege aktiviteit fan bepaalde immuunsellen giet. De behanneling fan de sykte is noch net maklik. Wy hawwe ferskate medisinen dy't it immuunsysteem ûnderdrukke of har aktiviteit feroarje. Njonken rjochtsje wy ús ek op it behanneljen fan de wûnen en it behearen fan pine. Corticosteroïden en cyclosporine binne faak de earste kar foar behanneling, mar de lêste tiid is der mear ûndersyk west nei it brûken fan biologyske terapyen lykas TNF‑α‑ynhibitoren. Dizze biologyske medisinen wurde hieltyd mear de foarkar, foaral by pasjinten mei oare inflammatoire omstannichheden, en se wurde earder brûkt yn it sykteproses.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
